logo
Stran & Company Achieves 95.2% Increase in Sales to Approximately $32.6 Million for the Second Quarter of 2025

Stran & Company Achieves 95.2% Increase in Sales to Approximately $32.6 Million for the Second Quarter of 2025

Globe and Mail2 days ago
Reports Positive Net Income for the Three and Six Months Ended June 30, 2025
Executes Share Repurchase Program and Maintains Strong Balance Sheet with Approximately $18.1 Million in Cash, Cash Equivalents, and Investments
Conference Call Scheduled for Wednesday, August 13th at 10:00 A.M. ET
QUINCY, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ('Stran' or the 'Company') (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading provider of outsourced marketing solutions specializing in promotional products and loyalty incentives, today announced its financial results for the three and six months ended June 30, 2025, and provided a business update. Management will host a conference call at 10:00 a.m. Eastern Time on Wednesday, August 13, 2025.
'We're excited to report a remarkable 95.2% year-over-year increase in sales, reaching approximately $32.6 million for the second quarter of 2025,' commented Andy Shape, Chief Executive Officer of Stran. 'Our gross profit increased by more than 80%, driven by robust organic sales growth of 30.4%. For the first half of 2025, sales climbed by 72.5% to roughly $61.3 million, with gross profit rising 65.6% to approximately $18.4 million. While the August 2024 addition of the Gander Group segment has impacted our overall margin mix, our continued sales momentum and strong financial results underscore Stran's resilience and leadership in the marketplace—even as many industry peers face headwinds.'
Mr. Shape continued, 'Our industry achievements were recently recognized by the Advertising Specialty Institute (ASI), which advanced Stran to #23 in its 2025 Counselor Top 40 distributors list, up from #27 last year. This distinction positions us among the largest and most influential promotional products distributors in North America, reflecting our sustained growth, innovative strategies, and unwavering commitment to client success. We're also proud to welcome new board members Mark Adams, Sarah Cummins, and Brian Posner, who bring a wealth of experience across media, private equity, sports, consumer brands, and public company finance. Their leadership significantly enhances our board's strategic perspective and aligns with our vision for continued operational excellence and innovation.'
Mr. Shape also stated, 'In addition, following our Combined 2024/2025 Annual Meeting of Stockholders, Stran is now fully compliant with all Nasdaq continued listing requirements, further solidifying our governance foundation as a public company. With a robust balance sheet featuring approximately $18.1 million in cash, cash equivalents, and investments, we remain well-positioned to pursue strategic growth opportunities and invest in long-term value creation. During the quarter, we executed our share repurchase program—acquiring approximately 110,000 shares at an average price of $1.32, for a total investment of about $145,600—demonstrating our confidence in the business and our steadfast commitment to shareholder value.'
Mr. Shape concluded, 'As we look ahead, our enhanced board, industry recognition, and disciplined financial strategy have set the stage for continued growth and success. Stran is excited to build on this momentum and deliver even greater value to our clients, team members, and shareholders.'
Financial Results for the Three Months ended June 30, 2025
Sales increased 95.2% to approximately $32.6 million for the three months ended June 30, 2025, from approximately $16.7 million for the three months ended June 30, 2024. Sales by the Stran segment (which consists of the Stran business not including the former Gander Group business) increased to approximately $21.8 million for the three months ended June 30, 2025 from approximately $16.7 million for the three months ended June 30, 2024. Sales by our SLS segment (which consists of the former Gander Group business) increased to approximately $10.8 million for the three months ended June 30, 2025 from $0 for the three months ended June 30, 2024.
Gross profit increased 80.5% to approximately $9.9 million, or 30.3% of sales, for the three months ended June 30, 2025, from approximately $5.5 million, or 32.8% of sales, for the three months ended June 30, 2024. Gross profit margin decreased to 30.3% for the three months ended June 30, 2025 from 32.8% for the three months ended June 30, 2024 primarily due to the acquisition of the Gander Group business in August 2024, which operates at a lower gross margin than the Stran segment.
Operating expenses increased 44.1% to approximately $9.5 million for the three months ended June 30, 2025, from approximately $6.6 million for the three months ended June 30, 2024. As a percentage of sales, operating expenses decreased to 29.1% for the three months ended June 30, 2025, from 39.4% for the three months ended June 30, 2024.
Net income for the three months ended June 30, 2025 was approximately $0.6 million, compared to net loss of approximately $(1.0) million for the three months ended June 30, 2024.
Financial Results for the Six Months ended June 30, 2025
Sales increased 72.5% to approximately $61.3 million for the six months ended June 30, 2025, from approximately $35.5 million for the six months ended June 30, 2024. Sales by the Stran segment increased to approximately $42.7 million for the six months ended June 30, 2025 from approximately $35.5 million for the six months ended June 30, 2024. Sales by the SLS segment increased to approximately $18.6 million for the six months ended June 30, 2025 from $0 for the six months ended June 30, 2024.
Gross profit increased 65.6% to approximately $18.4 million, or 30.0% of sales, for the six months ended June 30, 2025, from approximately $11.1 million, or 31.2% of sales, for the six months ended June 30, 2024. Gross profit margin decreased to 30.0% for the six months ended June 30, 2025 from 31.2% for the six months ended June 30, 2024 primarily due to the acquisition of the Gander Group business in August 2024, which operates at a lower gross margin than the Stran segment.
Operating expenses increased 43.8% to approximately $18.5 million for the six months ended June 30, 2025, from approximately $12.9 million for the six months ended June 30, 2024. As a percentage of sales, operating expenses decreased to 30.2% for the six months ended June 30, 2025, from 36.2% for the six months ended June 30, 2024.
Net income for the six months ended June 30, 2025 was approximately $0.3 million, compared to net loss of approximately $(1.5) million for the six months ended June 30, 2024.
Webcast and Conference Call
Management will host a webcast and conference call at 10:00 A.M. Eastern Time on Wednesday, August 13, 2025, to discuss the Company's financial results for the second quarter of 2025 ended June 30, 2025, as well as the Company's corporate progress and other developments.
The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and using entry code: 317692. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2855/52808 or on the company's Investors section of the website: ir.stran.com/news-events/ir-calendar.
A webcast replay will be available on the Investor Relations section of the Company's website (ir.stran.com/news-events/ir-calendar) through August 13, 2026. A telephone replay of the call will be available approximately one hour following the call, through August 27, 2025, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and entering conference ID: 52808.
About Stran
For over 30 years, Stran has grown to become a leader in the promotional products industry, specializing in complex marketing programs to help recognize the value of promotional products, branded merchandise, and loyalty incentive programs as a tool to drive awareness, build brands and impact sales. Stran is the chosen promotional programs manager of many Fortune 500 companies, across a variety of industries, to execute their promotional marketing, loyalty and incentive, sponsorship activation, recruitment, retention, and wellness campaigns. Stran provides world-class customer service and utilizes cutting-edge technology, including efficient ordering and logistics technology to provide order processing, warehousing and fulfillment functions. The Company's mission is to develop long-term relationships with its clients, enabling them to connect with both their customers and employees in order to build lasting brand loyalty. Additional information about the Company is available at: www.stran.com.
Forward Looking Statements
This press release contains 'forward-looking statements' that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' "will' 'would,' or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, the Company's expectations regarding synergies from its acquired businesses, its financial position and operating performance, its expectations regarding its business initiatives, the Company's expectations about its operating performance, trends in its business, the effectiveness of its growth strategies, its market opportunities, and demand for its products and services in general. Forward-looking statements are based on the Company's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled 'Risk Factors' in the Company's periodic reports which are filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law.
Contacts:
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share amounts)
June 30,
2025 December 31,
2024
(Unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents $ 13,070 $ 9,358
Investments 4,997 8,856
Accounts receivable, net 22,063 18,092
Accounts receivable - related parties, net 402 573
Inventory 6,736 5,389
Prepaid corporate taxes — 28
Prepaid expenses 2,391 2,308
Deposits 467 423
Other current assets 4 455
Total current assets 50,130 45,482
Property and equipment, net 1,618 1,701
OTHER ASSETS:
Intangible assets - customer lists, net 3,934 4,170
Intangible assets - trade name 654 654
Goodwill 2,321 2,321
Other assets 222 23
Right of use assets 2,336 797
Total other assets 9,467 7,965
Total assets $ 61,215 $ 55,148
LIABILITIES AND STOCKHOLDERS' EQUITY
CURRENT LIABILITIES:
Accounts payable and accrued expenses $ 9,513 $ 8,919
Accrued payroll and related 2,044 1,513
Unearned revenue 4,817 4,423
Rewards program liability 9,000 6,000
Sales tax payable 315 353
Corporate taxes payable 9 —
Current portion of contingent earn-out liabilities 105 256
Current portion of installment payment liabilities 158 365
Current portion of lease liabilities 661 366
Total current liabilities 26,622 22,195
LONG-TERM LIABILITIES:
Long-term contingent earn-out liabilities 455 455
Long-term installment payment liabilities 425 425
Long-term lease liabilities 1,880 432
Total long-term liabilities 2,760 1,312
Total liabilities 29,382 23,507
Commitments and contingencies
Preferred stock, $0.0001 par value; 50,000,000 shares authorized, 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively — —
Common stock, $0.0001 par value; 300,000,000 shares authorized, 18,546,461 and 18,598,574 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 2 2
Additional paid-in capital 38,285 38,391
Accumulated deficit (6,492) (6,742)
Accumulated other comprehensive income (loss) 38 (10)
Total stockholders' equity 31,833 31,641
Total liabilities and stockholders' equity $ 61,215 $ 55,148
For the Three Months Ended
June 30, For the Six Months Ended
June 30,
2025 2024 2025 2024
SALES
Sales $ 32,577 $ 16,693 $ 61,271 $ 35,474
Sales – related parties — — — 46
Total sales 32,577 16,693 61,271 35,520
COST OF SALES:
Cost of sales 22,708 11,226 42,920 24,405
Cost of sales - related parties — — — 35
Total cost of sales 22,708 11,226 42,920 24,440
GROSS PROFIT 9,869 5,467 18,351 11,080
OPERATING EXPENSES:
General and administrative expenses 9,474 6,575 18,491 12,857
Total operating expenses 9,474 6,575 18,491 12,857
INCOME (LOSS) FROM OPERATIONS 395 (1,108) (140) (1,777)
OTHER INCOME:
Other income 285 1 280 16
Interest income 77 82 119 175
Realized gain on investments — 3 67 73
Total other income 362 86 466 264
INCOME (LOSS) BEFORE INCOME TAXES 757 (1,022) 326 (1,513)
Provision for income taxes 114 3 76 3
NET INCOME (LOSS) $ 643 $ (1,025) $ 250 $ (1,516)
NET INCOME (LOSS) PER COMMON SHARE
Basic $ 0.03 $ (0.06) $ 0.01 $ (0.08)
Diluted $ 0.03 $ (0.06) $ 0.01 $ (0.08)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
Basic 18,592,339 18,589,086 18,600,373 18,581,957
2025 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss) $ 250 $ (1,516)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization 521 341
Noncash operating lease expense 537 274
Change in allowance for credit losses 360 (288)
Noncash interest accretion 23 72
Stock-based compensation 40 170
Changes in operating assets and liabilities:
Accounts receivable, net (4,331) 4,496
Accounts receivable – related parties, net 172 25
Inventory (1,347) 808
Prepaid corporate taxes 29 30
Prepaid expenses (82) 336
Deposits (44) (193)
Other assets 252 —
Accounts payable and accrued expenses 590 (871)
Accrued payroll and related 531 (1,357)
Unearned revenue 395 (262)
Rewards program liability 3,000 2,475
Sales tax payable (38) (117)
Corporate taxes payable 9 —
Operating lease liabilities (333) (256)
Net cash provided by operating activities 534 4,167
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property and equipment (202) (364)
Proceeds from sale of investments 4,400 4,608
Purchase of investments (493) (3,836)
Net cash provided by investing activities 3,705 408
CASH FLOWS FROM FINANCING ACTIVITIES:
Payment of contingent earn-out liabilities (151) —
Payment of installment payment liabilities (230) (760)
Payment for stock repurchase (146) —
Net cash used in financing activities (527) (760)
NET INCREASE IN CASH 3,712 3,815
CASH AND CASH EQUIVALENTS - BEGINNING 9,358 8,059
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Profound Medical Posts Wider Loss in Q2
Profound Medical Posts Wider Loss in Q2

Globe and Mail

time22 minutes ago

  • Globe and Mail

Profound Medical Posts Wider Loss in Q2

Key Points Revenue (GAAP) declined slightly year over year to $2.2 million in Q2 2025, missing GAAP revenue estimates by 32.3% on delayed capital sales. Operating expenses (GAAP) climbed approximately 65.8%, pushing net loss (GAAP) to $15.7 million, Net loss for the quarter ended June 30, 2025, increased approximately 127.5% year over year. Management reiterated its annual revenue growth target of 70–75% year-over-year in 2025; with the outlook relying on a sharp second-half rebound in 2025. These 10 stocks could mint the next wave of millionaires › Profound Medical (NASDAQ:PROF), a medical technology company specializing in minimally invasive prostate therapies, reported its GAAP financial results for Q2 2025 on August 14, 2025. The company reported no GAAP revenue growth compared to the prior-year period, with total GAAP revenue of $2.2 million, well below analysts' expectations of $3.25 million. The company's net loss widened to $15.7 million, or $0.52 per share (GAAP). The quarter saw higher operating costs and a delay in capital equipment deals, contributing to weaker-than-expected performance. Despite these headwinds, management reaffirmed its full-year 2025 guidance for strong revenue growth in the approximate range of 70% to 75% year-over-year, but the results highlight ongoing execution risks. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. Business Snapshot and Strategic Priorities Profound Medical develops technologies for image-guided, minimally invasive treatments for prostate diseases. Its flagship TULSA-PRO system enables physicians to ablate (destroy) prostate tissue using real-time magnetic resonance imaging (MRI) and high-intensity ultrasound. The Sonalleve system, another platform, is used for the treatment of uterine fibroids and other conditions with focused ultrasound. The company's near-term focus is to expand adoption of its TULSA-PRO system in the U.S. and abroad, leveraging recent regulatory wins and reimbursement changes. Key to success are continued clinical validation, conversion of sales pipeline opportunities into system placements, and growing a reliable stream of recurring revenue from consumables, leases, and services tied to each installed system. Profound Medical's ability to manage costs and extend its cash runway until recurring revenue can support operations is also critical, given its current reliance on external funding. Quarter in Review: Operations and Financials The company experienced a stalled top line, reporting $2.2 million in GAAP revenue for Q2 2025—virtually unchanged from the prior year and substantially below consensus estimates. This GAAP revenue miss was attributed to short-term delays in closing several capital sales for TULSA-PRO systems. According to management, had these deals been completed during the quarter, revenue would have topped $3 million. Recurring revenue from procedures, disposables, and service grew by 6.9%, rising from $1.46 million in Q2 2024 to $1.56 million in Q2 2025 (GAAP), and accounted for most of the total revenue. Sales of capital equipment dropped slightly, reflecting the postponed deals. Meanwhile, procedure volumes continued to rise at existing customer sites, with 'same-store' utilization up 10% from Q1 2025. The sales pipeline for new TULSA-PRO system placements increased, with 80 systems in advanced negotiation stages as of quarter end. This suggests strong demand, but actual conversion of this pipeline into revenue remains a known risk. The company's product portfolio saw notable milestones: The TULSA-AI Volume Reduction Module—an artificial intelligence-based add-on for treating benign prostatic hyperplasia (BPH)—completed its first commercial procedure and soft-launched at five sites, with a full release planned for the fourth quarter of 2025. Profound Medical also continued to develop 'TULSA+,' a program to bundle TULSA-PRO with MRI scanners from Siemens, with commercial sales expected to launch before the end of 2025. The TULSA-PRO system received important clinical validation during the period. Initial data from the CAPTAIN randomized trial showed the device provides a statistically significant improvement in post-operative experience compared to traditional robotic prostatectomy—patients experienced no blood loss, faster recovery, and less pain. This data gives the product a competitive edge and is being rolled out at key clinical meetings to boost awareness and drive adoption. Gross margin (GAAP) improved to 73%, up from 64% a year earlier in Q2 2025, reflecting more efficient manufacturing. However, the gain could not offset a jump in operating costs, which rose approximately 65.6% year-over-year to $15.4 million (GAAP). Research and development (R&D) spending rose to $6.1 million (GAAP). Selling, general, and administrative (SG&A) costs (GAAP) climbed to $9.3 million as Profound Medical increased headcount and built up commercial infrastructure to support market expansion and the CAPTAIN trial. The net loss (GAAP) widened to $15.7 million, up from $6.9 million in Q2 2024. Higher expenses with no corresponding revenue growth drove this result. Profound Medical ended Q2 2025 with $35.2 million in cash (GAAP), down from $54.9 million at December 31, 2024 (GAAP). Inventory levels also increased to $8.35 million (GAAP) as of quarter end, but the results highlight ongoing execution risks. Looking Forward For the remainder of FY2025, management maintained its guidance for total annual revenue growth of 70–75%, despite the weak first-half result. Achieving this will depend on a sharp ramp-up in capital systems sales and recurring revenue in the second half of 2025. This reflects management's expectation for a stronger pipeline conversion as new reimbursement codes, clinical data, and product launches come to fruition. The company stated that a 'back-end loaded' revenue profile is anticipated for 2025, consistent with the shift toward upfront capital equipment sales. Meeting these ambitious targets will require improved execution and more predictable closing of sales, as well as continued clinical advocacy of the TULSA-PRO platform. Investors should monitor: the rate at which pipeline deals materialize into revenue; expense growth relative to sales; and ongoing improvements in the balance of recurring versus one-time capital sales. PROF does not currently pay a dividend. Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted. Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor's total average return is 1,062%* — a market-crushing outperformance compared to 185% for the S&P 500. They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor. See the stocks » *Stock Advisor returns as of August 13, 2025 JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Braze (BRZE): A Promising Player in Marketing Tech or Just Another Risky Bet?
Braze (BRZE): A Promising Player in Marketing Tech or Just Another Risky Bet?

Globe and Mail

time37 minutes ago

  • Globe and Mail

Braze (BRZE): A Promising Player in Marketing Tech or Just Another Risky Bet?

Explore the exciting world of Braze (NASDAQ: BRZE) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Jul. 16, 2025. The video was published on Aug. 14, 2025. Should you invest $1,000 in Braze right now? Before you buy stock in Braze, consider this: Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Braze wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,544!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,113,059!* Now, it's worth noting Stock Advisor's total average return is 1,062% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025

Best Generative Engine Optimization Companies 2025: Algomizer Tops the List
Best Generative Engine Optimization Companies 2025: Algomizer Tops the List

Globe and Mail

time37 minutes ago

  • Globe and Mail

Best Generative Engine Optimization Companies 2025: Algomizer Tops the List

Algomizer ranked #1 in Generative Engine Optimization for 2025 - helping brands dominate AI answers and rankings from ChatGPT, Claude, Perplexity & more. New York, NY - August 14, 2025 - Algomizer, the pioneer in Generative Engine Optimization (GEO), has been named the #1 company in its category by leading AI marketing analysts. Specializing in helping enterprises and brands appear in the right place - inside the answers of large language models (LLMs). Algomizer equips companies globally with actionable insights and measurable results in the fast-changing world of AI-driven discovery. Over 500 million people now use AI to find products, services, and information. Traditional approaches don't guarantee visibility inside ChatGPT, Perplexity or Claude's responses - but Algomizer does. The company's proprietary LLM optimization methods, visibility tracking tools, and prompt intelligence insights help brands secure prime placement in generative search results, where buying decisions increasingly happen. Algomizer's services include: LLM Optimization – Improve brand mentions and positioning inside AI-generated answers. Visibility Tracking - Monitor where and how your brand is mentioned in AI-generated answers across platforms. Brand Intelligence -Understand how AI interprets, presents and engages with your brand — and why. Prompt & Topic Exploration – Discover the questions people are asking AI where your brand should appear — but doesn't. Custom Alerts – Get proactive updates before negative AI mentions impact sales. Clients from SaaS startups to global eCommerce leaders credit Algomizer with measurable wins — from boosting AI visibility by 87% in a quarter to tripling ROI in under six months. Recognized as the best in Generative Engine Optimization for 2025, Algomizer's methods prepare brands for the next wave of AI search — from voice interfaces to multimodal results — giving them a lasting competitive edge in markets like SaaS, finance, and retail. About Algomizer Algomizer is the leading Generative Engine Optimization company, helping brands win visibility inside AI platforms like ChatGPT, Claude, Perplexity, and more. Through proprietary LLM optimization techniques, visibility intelligence, and enterprise-ready infrastructure, Algomizer delivers rapid, measurable improvements in AI-driven brand presence. Learn more at

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store